Your browser doesn't support javascript.
loading
Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures.
Boulé, Stéphane; Marquié, Christelle; Vanesson-Bricout, Claire; Kouakam, Claude; Brigadeau, François; Guédon-Moreau, Laurence; Acheré, Charles; Goéminne-Boulé, Céline; Lacroix, Dominique; Klug, Didier; Kacet, Salem.
Afiliación
  • Boulé S; Department of Cardiovascular Medicine, Lille University Hospital, Lille, France. stephane.boule@chru-lille.fr
Pacing Clin Electrophysiol ; 35(5): 605-11, 2012 May.
Article en En | MEDLINE | ID: mdl-22432791
ABSTRACT

BACKGROUND:

Management of antiplatelet therapy at the time of device implantation remains controversial. This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery.

METHODS:

We performed a retrospective case-control study. Between 2004 and 2010, 101 consecutive patients receiving clopidogrel underwent cardiac device surgery (pacemaker or implantable cardioverter-defibrillator implantation, and generator replacement) in our institution. Controls were 11 matched on age, sex, device, type of procedure, number of leads implanted, and venous approach (cephalic or subclavian). A significant bleeding complication was defined as pocket hematoma requiring surgical evacuation or prolonged hospitalization, hemothorax, pericardial effusion, or tamponade.

RESULTS:

Bleeding complications occurred more frequently in patients receiving clopidogrel at the time of device procedure 11.9% versus 4.0% (P = 0.037; odds radio [OR] 3.27 [1.02-10.5]). Significant bleeding complications were noted in 12 patients (11.9%) receiving clopidogrel, including two patients with pericardial effusion and one patient with hemothorax. Four controls (4.0%) had bleeding complications (three pocket hematomas and one pericardial effusion). The single factor associated with increased bleeding complications in patients receiving clopidogrel was subclavian puncture (P = 0.008). In the entire cohort (n = 202), multivariate analysis identified two independent predictors of significant bleeding complications clopidogrel treatment at the time of surgery (P = 0.03; OR 3.7 [1.1-12.6]) and subclavian venous puncture (P = 0.03; OR 3.44 [1.1-10.4]).

CONCLUSIONS:

Clopidogrel treatment at the time of heart rhythm device procedures is associated with an increased risk of significant bleeding complications. Subclavian puncture seems to strongly increase hemorrhagic complications in this setting.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trombosis / Ticlopidina / Terapia de Resincronización Cardíaca / Hemorragia Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Pacing Clin Electrophysiol Año: 2012 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trombosis / Ticlopidina / Terapia de Resincronización Cardíaca / Hemorragia Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Pacing Clin Electrophysiol Año: 2012 Tipo del documento: Article País de afiliación: Francia